Skip to main content
. 2017 Apr 6;83(8):1815–1825. doi: 10.1111/bcp.13269

Figure 2.

Figure 2

Comparison of (A) dose‐normalized maximum plasma concentrations (C max) of idarucizumab for all subjects with normal renal function who received a single 5‐min idarucizumab infusion and (B) dose‐normalized area under the plasma idarucizumab concentration–time curve (AUC0–∞) values for all subjects with normal renal function with and without pre‐existing anti‐idarucizumab antibodies; pooled data from the three Phase I studies. ADA, antidrug antibodies; AUC, area under the curve; C max, maximum plasma concentration; P5, P10, P90 and P95, 5th, 10th, 90th and 95th centiles